Monday, February 25, 2013

Europe: Is National Drug Pricing Freedom Nearing its Expiry Date?

Media_httpblogpharmex_bafqe

Underlying the calls for cheaper drugs, wider access, and tighter controls on the drug industry is a new momentum that comes not just from those automatically hostile to drug firms, but from a still more influential community: Europe’s ministers of finance and economic affairs. These fresh and even more formidable pressures are evident in a strategy document released by the European Commission in February, entitled “Investing in Health.” It aims to draw conclusions by the end of 2013 on “responses to health system challenges, in particular in relation to integrated care and the use of pharmaceuticals,” with special emphasis on “measuring and monitoring the effectiveness of health investments.”

Posted via email from Jack's posterous

No comments: